Lisa von Moltke - 15 Apr 2025 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Role
Head of Research and Development and Chief Medical Officer
Signature
By: /s/ Chase Jayasekera, Attorney-in-Fact
Issuer symbol
ZBIO
Transactions as of
15 Apr 2025
Net transactions value
$0
Form type
4
Filing time
17 Apr 2025, 16:01:17 UTC
Previous filing
21 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZBIO Stock Option (Right to Buy) Award $0 +400,000 $0.000000 400,000 15 Apr 2025 Common Stock 400,000 $8.72 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% of the underlying shares of common stock on March 17, 2025, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal month installments over 36 months thereafter, subject to continued service.

Remarks:

Head of Research and Development and Chief Medical Officer